YK-11

YK-11
Clinical data
Other namesYK11; myostine; (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester
Drug classSelective androgen receptor modulator
Identifiers
  • Methyl (2E)-2-[(8R,9S,10R,13S,14S,17S)-2'-methoxy-2',13-dimethyl-3-oxospiro[1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-17,5'-1,3-dioxolane]-4'-ylidene]acetate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC25H34O6
Molar mass430.541 g·mol−1
3D model (JSmol)
  • C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@]24/C(=C\C(=O)OC)/OC(O4)(C)OC)CCC5=CC(=O)CC[C@H]35
  • InChI=1S/C25H34O6/c1-23-11-9-18-17-8-6-16(26)13-15(17)5-7-19(18)20(23)10-12-25(23)21(14-22(27)28-3)30-24(2,29-4)31-25/h13-14,17-20H,5-12H2,1-4H3/b21-14+/t17-,18+,19+,20-,23-,24?,25+/m0/s1
  • Key:KCQHQCDHFVGNMK-PQUNLUOYSA-N

YK-11 is a synthetic steroidal selective androgen receptor modulator (SARM).[1][2] It is a gene-selective partial agonist of the androgen receptor (AR) and does not induce the physical interaction between the NTD/AF1 and LBD/AF2 (known as the N/C interaction), which is required for full transactivation of the AR.[1][2] The drug has anabolic activity in vitro in C2C12 myoblasts and shows greater potency than dihydrotestosterone (DHT) in this regard.[2] It has been investigated as a potential treatment for sepsis-induced muscle wasting in animal studies.[3] YK-11 has been encountered as a novel designer drug.[4]

In 2022, Health Canada warned that SARMs such as myostine (YK-11) "are not authorized in Canada for any use and have not been reviewed by Health Canada for safety, effectiveness and quality. The use of bodybuilding products that contain SARMs can pose serious health risks such as heart attack, stroke and liver damage. The long-term effects on the body are unknown."[5]

See also

References

  1. ^ a b Kanno Y, Hikosaka R, Zhang SY, Inoue Y, Nakahama T, Kato K, et al. (2011). "(17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor". Biological & Pharmaceutical Bulletin. 34 (3): 318–323. doi:10.1248/bpb.34.318. PMID 21372378.
  2. ^ a b c Kanno Y, Ota R, Someya K, Kusakabe T, Kato K, Inouye Y (2013). "Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression". Biological & Pharmaceutical Bulletin. 36 (9): 1460–1465. doi:10.1248/bpb.b13-00231. PMID 23995658.
  3. ^ Lee SJ, Gharbi A, Shin JE, Jung ID, Park YM (March 2021). "Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis". Biochemical and Biophysical Research Communications. 543: 1–7. doi:10.1016/j.bbrc.2021.01.030. PMID 33588136.
  4. ^ "YK-11". АИПСИН (in Russian). Retrieved 6 January 2026.
  5. ^ "Unauthorized products may pose serious health risks (March 26, 2021 to June 3, 2022) - Recalls, advisories and safety alerts". Government of Canada. 2022-06-03. Retrieved 2026-01-15.
allikas: https://en.wikipedia.org/wiki/YK-11